Mantis Therapeutics was accepted into the next round of the highly competitive OncoStars programme.
Mantis Therapeutics has received approval of a US patent protecting the intellectual property concerning our innovative anti-cancer immunotherapy.
Mantis Therapeutics acquired new laboratorium space at the Bio Science Park in Leiden. In this environment directed towards innovation we will further develop our innovative therapy and grow as a company.
Mantis Therapeutics was one of 10 companies, and the only non-UK company, invited to join in the OncoStars programme of Cancer Research UK.
Mantis Therapeutics has received approval of an EU patent protecting the intellectual property concerning our innovative anti-cancer immunotherapy.
Mantis Therapeutics was invited to join the Dutch king and queen on a trading mission to India. Indian hospital directors expressed their interest in collaborating in the development of BaCure.
Mantis Therapeutics received a Eureka Globalstars Grant for the development of a Drug Delivery Platform in collaboration with a relevant Indian partner.